Skip to main content

Symposium on Hidradenitis Suppurativa Advances (SHSA), 2025

Filter
Close
Content type:
Bimekizumab Mental Health Outcomes in Patients with HS: 2-Year Data from BE HEARD EXT
Christopher J. Sayed, Bruce Strober, Hadar Lev-Tov, et al.
Poster
Bimekizumab Lesion Resolution Over 3 Years in HS: Results from BE HEARD I&II and BE HEARD EXT
Amit Garg, Martina L. Porter, Steven Daveluy, et al.
Poster
Bimekizumab Reduces Draining Tunnel Count Over 3 Years in HS: Data from BE HEARD EXT
Jennifer Hsiao, Haley B. Naik, Alexa B. Kimball, et al.
Poster
Bimekizumab 3-Year Efficacy and Safety in Patients with HS: Results from BE HEARD I&II and EXT
John R. Ingram, Alexa B. Kimball, Amit Garg, et al.
Poster
Bimekizumab Improves HSSQ Skin Pain over 3 Years in HS: Data from BE HEARD EXT
Hadar Lev-Tov, Lauren A.V. Orenstein, Vivian Y. Shi, et al.
Poster
A Longitudinal Study of Quality of Life and Depression in Patients with Hidradenitis Suppurativa
Sahar Caravan, Helena Andres-Terre, Victoria Harbour, et al.
Poster